• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

HIV vaccine development in the aftermath of the STEP study: re-focus on occult HIV infection?

作者信息

Uberla Klaus

机构信息

Department of Molecular and Medical Virology, Ruhr-University Bochum, Bochum, Germany.

出版信息

PLoS Pathog. 2008 Aug 29;4(8):e1000114. doi: 10.1371/journal.ppat.1000114.

DOI:10.1371/journal.ppat.1000114
PMID:18769723
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2517652/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccf1/2517652/2a5be78c283b/ppat.1000114.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccf1/2517652/2a5be78c283b/ppat.1000114.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccf1/2517652/2a5be78c283b/ppat.1000114.g001.jpg

相似文献

1
HIV vaccine development in the aftermath of the STEP study: re-focus on occult HIV infection?STEP研究之后的HIV疫苗研发：重新聚焦于隐匿性HIV感染？
PLoS Pathog. 2008 Aug 29;4(8):e1000114. doi: 10.1371/journal.ppat.1000114.
2
HIV vaccine efficacy trials: towards the future of HIV prevention.HIV疫苗效力试验：迈向HIV预防的未来
Infect Dis Clin North Am. 2007 Mar;21(1):201-17, x. doi: 10.1016/j.idc.2007.01.006.
3
HIV vaccines. Viral envelope fails to deliver?艾滋病毒疫苗。病毒包膜未能发挥作用？
Nature. 1998 Feb 12;391(6668):638-9. doi: 10.1038/35504.
4
HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation.
AIDS Res Hum Retroviruses. 1997 Feb 10;13(3):211-6. doi: 10.1089/aid.1997.13.211.
5
Post-step modifications for research on HIV vaccines.用于HIV疫苗研究的步骤后修饰
AIDS. 2009 Jan 2;23(1):3-8. doi: 10.1097/QAD.0b013e32830e6d6d.
6
HIV/AIDS vaccines: a need for new concepts?艾滋病毒/艾滋病疫苗：是否需要新的概念？
Int Rev Immunol. 2008;27(6):447-71. doi: 10.1080/08830180802432160.
7
HIV adenovirus vaccine in Phase I trials.处于一期试验阶段的HIV腺病毒疫苗。
Expert Rev Vaccines. 2003 Aug;2(4):471.
8
What hope is there for an HIV vaccine?艾滋病疫苗的前景如何？
S Afr Med J. 2004 Oct;94(10):831.
9
Neutralizing antibodies against HIV -- back in the major leagues?抗HIV中和抗体——重归主流了？
Curr Opin Immunol. 2002 Aug;14(4):495-502. doi: 10.1016/s0952-7915(02)00362-x.
10
Progress toward an HIV vaccine.艾滋病疫苗的进展。
Annu Rev Med. 2005;56:213-23. doi: 10.1146/annurev.med.54.101601.152349.

引用本文的文献

1
Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development.人类和动物模型中与疫苗相关的增强疾病：疫苗开发的经验与挑战
Front Microbiol. 2022 Aug 10;13:932408. doi: 10.3389/fmicb.2022.932408. eCollection 2022.
2
Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans.气溶胶传递而非肌肉注射腺病毒载体结核疫苗可诱导人体呼吸道黏膜免疫。
JCI Insight. 2022 Feb 8;7(3):e155655. doi: 10.1172/jci.insight.155655.
3
Defining Kinetic Properties of HIV-Specific CD8⁺ T-Cell Responses in Acute Infection.

本文引用的文献

1
The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.诱导针对HIV-1和流感病毒的中和抗体所面临的挑战。
Nat Rev Microbiol. 2008 Feb;6(2):143-55. doi: 10.1038/nrmicro1819.
2
Induction of potent local cellular immunity with low dose X4 SHIV(SF33A) vaginal exposure.低剂量X4 SHIV（SF33A）经阴道暴露诱导强效局部细胞免疫。
Virology. 2007 Oct 10;367(1):196-211. doi: 10.1016/j.virol.2007.05.021. Epub 2007 Jun 15.
3
Perils at mucosal front lines for HIV and SIV and their hosts.HIV和SIV及其宿主在黏膜前沿面临的风险。
定义急性感染中HIV特异性CD8⁺ T细胞反应的动力学特性。
Microorganisms. 2019 Mar 4;7(3):69. doi: 10.3390/microorganisms7030069.
4
Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.溶瘤腺病毒：载体设计与免疫溶瘤应用的策略与见解
Viruses. 2015 Nov 24;7(11):6009-42. doi: 10.3390/v7112923.
5
Designer antigens for elicitation of broadly neutralizing antibodies against HIV.设计用于诱导针对 HIV 的广泛中和抗体的抗原。
Clin Transl Immunology. 2014 Sep 26;3(9):e24. doi: 10.1038/cti.2014.22. eCollection 2014 Sep.
6
Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency.热休克蛋白70（HSP70）的编码新形式或一种溶细胞蛋白可提高DNA疫苗的效力。
Hum Vaccin Immunother. 2014;10(9):2679-83. doi: 10.4161/hv.29527. Epub 2014 Nov 19.
7
Cellular superspreaders: an epidemiological perspective on HIV infection inside the body.细胞超级传播者：体内HIV感染的流行病学视角
PLoS Pathog. 2014 May 8;10(5):e1004092. doi: 10.1371/journal.ppat.1004092. eCollection 2014 May.
8
The two faces of vaccine-induced immune response: protection or increased risk of HIV infection?!疫苗诱导的免疫反应的两面性：保护作用还是增加感染艾滋病毒的风险？
Virol Sin. 2014 Feb;29(1):7-9. doi: 10.1007/s12250-014-3419-9.
9
Interleukin-encoding adenoviral vectors as genetic adjuvant for vaccination against retroviral infection.白细胞介素编码腺病毒载体作为逆转录病毒感染疫苗的遗传佐剂。
PLoS One. 2013 Dec 4;8(12):e82528. doi: 10.1371/journal.pone.0082528. eCollection 2013.
10
Risk of immunodeficiency virus infection may increase with vaccine-induced immune response.疫苗诱导的免疫反应可能会增加感染艾滋病毒的风险。
J Virol. 2012 Oct;86(19):10533-9. doi: 10.1128/JVI.00796-12. Epub 2012 Jul 18.
Nat Rev Immunol. 2005 Oct;5(10):783-92. doi: 10.1038/nri1706.
4
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.一项用于预防HIV-1感染的重组糖蛋白120疫苗的安慰剂对照3期试验。
J Infect Dis. 2005 Mar 1;191(5):654-65. doi: 10.1086/428404. Epub 2005 Jan 27.
5
Resistance to HIV-1 infection: lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals.对HIV-1感染的抵抗：从对长期高暴露但持续血清阴性（HEPS）个体的研究中获得的经验教训。
AIDS Rev. 2003 Apr-Jun;5(2):87-103.
6
Occult systemic infection and persistent simian immunodeficiency virus (SIV)-specific CD4(+)-T-cell proliferative responses in rhesus macaques that were transiently viremic after intravaginal inoculation of SIV.恒河猴经阴道接种猴免疫缺陷病毒（SIV）后短暂病毒血症期间的隐匿性全身感染及持续性SIV特异性CD4(+) T细胞增殖反应
J Virol. 1998 Dec;72(12):10029-35. doi: 10.1128/JVI.72.12.10029-10035.1998.
7
Immune responses in HIV-exposed seronegatives: have they repelled the virus?
Curr Opin Immunol. 1995 Aug;7(4):448-55. doi: 10.1016/0952-7915(95)80087-5.